New York, NY, United States of America

Tae Chung

This inventor holds 2 USPTO granted patents. Top assignee: Takeda Vaccines, Inc.. Active years: 2024-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tae Chung. Retrieved from https://idiyas.com/inventor/tae-chung

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 50.0

Average Co-Inventor Count = 1.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2024-2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Tae Chung

Tae Chung is a notable inventor based in New York, NY, who has made significant strides in the field of pharmaceutical packaging. With a focus on enhancing the safety and efficacy of medication delivery, his work has garnered attention in the pharmaceutical industry.

Latest Patents

Tae Chung holds 1 patent for his innovative pharmaceutical packaging solution. This patent reflects his commitment to improving the way medications are stored and delivered, ensuring that they remain effective and safe for consumers.

Career Highlights

Currently, Tae Chung is employed at Takeda Vaccines, Inc., a leading company in the pharmaceutical sector. His role at Takeda allows him to apply his inventive skills to real-world challenges, contributing to the development of advanced healthcare solutions.

Collaborations

Due to space constraints, the details of collaborations will not be included.

Conclusion

Tae Chung's contributions to pharmaceutical packaging exemplify the impact of innovation in healthcare. His work not only enhances medication safety but also reflects the importance of continuous improvement in the pharmaceutical industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…